A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Clinical trial NCT03033914 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03033914
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-25
- Primary completion
- 2027-01-01
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.